New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2012
10:00 EDTMDLZ, RCL, TEVA, BXP, VOLC, ZIOP, XEL, SF, STX, PTEN, NVS, NOV, IEXOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: IDEX Corp. (IEX) downgraded to Hold from Buy at Brean Capital... National Oilwell (NOV) downgraded to Outperform from Buy at CLSA... Novartis (NVS) downgraded to Hold from Buy at Deutsche Bank... Patterson-UTI Energy (PTEN) downgraded to Outperform from Buy at CLSA... Seagate (STX) downgraded to Underweight from Neutral at JPMorgan... Stifel Financial (SF) downgraded to Underperform from Market Perform at Wells Fargo... Xcel Energy (XEL) downgraded to Neutral from Outperform at Macquarie... Ziopharm (ZIOP) downgraded to Hold from Buy at Jefferies... Boston Properties (BXP) downgraded to Hold from Buy at Stifel Nicolaus... Volcano (VOLC) downgraded to Neutral from Outperform at Credit Suisse... Teva (TEVA) downgraded to Market Perform from Outperform at Leerink... Royal Caribbean (RCL) downgraded to Neutral from Buy at Longbow... Mondelez (MDLZ) downgraded to Hold from Buy at Argus.
News For IEX;NOV;NVS;PTEN;STX;SF;XEL;ZIOP;VOLC;BXP;TEVA;RCL;MDLZ From The Last 14 Days
Check below for free stories on IEX;NOV;NVS;PTEN;STX;SF;XEL;ZIOP;VOLC;BXP;TEVA;RCL;MDLZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 15, 2014
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
05:44 EDTNVSNovartis to license Google 'smart lens' technology
Novartis (NVS) announced that its eye care division Alcon has entered into an agreement with a division of Google (GOOG) to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to transform eye care and further enhance Alcon's pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals. The agreement between Google and Alcon represents an important step for Novartis, across all of its divisions, to leverage technology to manage human diseases and conditions. Google's key advances in the miniaturization of electronics complement Novartis's deep pharmaceuticals and medical device expertise. Novartis aims to enhance the ways in which diseases are mapped within the body and ultimately prevented.
05:35 EDTNVSNovartis collaborates with Banner Alzheimer's Institute on study
Novartis announced a collaboration with Banner Alzheimer's Institute, or BAI, on a pioneering clinical study in Alzheimer's disease, or AD, prevention. The study will determine whether two Novartis investigational anti-amyloid treatments can prevent or delay the emergence of symptoms of AD in people identified as being at genetic risk for developing the late-onset form of the disease. Using an innovative trial design, the two treatments will be given in cognitively healthy people at genetic risk of developing the build-up of amyloid protein in the brain that may eventually lead to AD. One treatment is an active immunotherapy, a treatment that stimulates an immune response, and triggers the production of natural antibodies against amyloid. This investigational treatment, given via an injection, is in phase II clinical development. The second treatment, a BACE inhibitor, is an oral medication about to enter phase I trials and is designed to prevent the production of different forms of amyloid.
July 14, 2014
16:39 EDTSTXSeagate initiated with a Positive at Susquehanna
Subscribe for More Information
10:03 EDTMDLZOptions with increasing implied volatility: GNC SD MDLZ ETP
09:55 EDTPTENHigh option volume stocks: PTEN MFRM GTIV SHPG IMMR
08:34 EDTSTXPC market stability could be short-lived, Reuters says
Subscribe for More Information
08:04 EDTTEVATeva announces FDA acceptance of NDA filing for albuterol MDPI
Teva Pharmaceuticals Industries announced that the U.S. Food and Drug Administration has accepted for review the company’s new drug application for albuterol multi-dose dry-powder inhaler, an investigational breath-actuated dry-powder inhaler for the treatment or prevention of bronchospasm in patients 12 years of age and older with reversible obstructive airway disease; and for the prevention of exercise-induced bronchospasm in patients 12 years of age and older. The NDA filing includes data from eight clinical studies that evaluated the safety and efficacy of albuterol MDPI in adults and adolescents with asthma and exercise-induced bronchospasm. The NDA for albuterol MDPI has been accepted by the FDA for standard review, with a FDA Regulatory Action expected in March 2015.
07:23 EDTNVSAlzheimer's Association to hold a conference
Subscribe for More Information
06:57 EDTSTXSeagate price target raised to $74 from $64 at Deutsche Bank
Subscribe for More Information
06:27 EDTMDLZLindt & Sprüngli acquires Russell Stover Candies
The Lindt & Sprüngli Group is acquiring the traditional U.S. family business Russell Stover Candies, headquartered in Kansas City, Missouri. Lindt & Sprüngli is financing the acquisition through net cash resources and bank loans and expects the transaction to make a strong positive contribution to the earnings per share from 2015 onwards. It has been agreed not to disclose the purchase price and other contractual details. Other companies that are in the confectionary industry in North America include Hershey (HYS) Rocky Mountain Chocolate (RMCF) and Mondelez (MDLZ). Reference Link
July 11, 2014
14:58 EDTMDLZMondelez divestiture unlikely, says JPMorgan
Subscribe for More Information
13:22 EDTMDLZMondelez separating EU cheese biz as possible precursor to sale, Bloomberg says
Subscribe for More Information
08:49 EDTSTXJune CIO survey indicates strong 2H, says Morgan Stanley
Subscribe for More Information
07:11 EDTPTENPatterson-UTI Energy price target raised to $44 from $39 at RBC Capital
RBC Capital increased its price target on Patterson-UTI Energy as the firm is positive on the outlook for U.S. land drillers and likes the company's frac operating leverage, improving cash margins and valuation. The firm keeps an Outperform rating on the shares.
July 10, 2014
15:43 EDTNVSNovartis siponimod designated as orphan treatment of dermatomyositis
Subscribe for More Information
09:13 EDTSTXHP Western Digital Seagate to benefit from PC rebound, says RBC Capital
Subscribe for More Information
July 9, 2014
11:51 EDTSTXOptions with increasing implied volatility:
Subscribe for More Information
07:15 EDTTEVATeva, others fined $583.4M by EU regulators, Reuters says
Subscribe for More Information
06:49 EDTTEVAGeneric drug prices have risen significantly, NY Times says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use